William Plunkett, Ph.D.
Department of Experimental Therapeutics, Division of Cancer Medicine
About Dr. Plunkett
My major research pursuits are related to development of novel therapeutics based on knowledge of cellular responses to DNA damage, and elucidating the mechanisms of drug action, particularly of nucleoside analogs. Investigations by my group demonstrated multiple mechanism of action for both fludarabine and gemcitabine, as well as the mechanisms of other nucleosides. I have enjoyed sustained and dedicated collaborations with his colleagues involved with clinical research, interactions that have resulted in advances in clinical treatments that induce remissions more effectively and are maintained them longer than previously possible in leukemias. I was the recipient of the Service to Mankind Award from the Leukemia Society of America in 1989, the Faculty Achievement Award in Clinical Research in 1996, and the 1 st Potu N. Rao award for Excellence in Basic Research in 2006, and the Waun Ki Hong Achievement Award for Team Research - CLL in 2011. I was elected a Fellow of the American Association for the Advancement of Science in 2012. I was the 2013 recipient of the Charles A. LeMaistre, M.D. Outstanding Acheivement Award in Cancer and received the John Mendelsohn Lifetime Scientific Achievement Award in 2016. Under the title of Associate Vice President, Research Integrity, I have assumed the responsibilities of the Institutional Research Integrity Officer since 2007.
I am particularly interested in education of the next generation of scientists. He has been a member of the University of Texas Graduate School of Biomedical Sciences at Houston since 1976. His activities in graduate education have been recognized by his election to President of the Faculty of The Graduate School of Biomedical Sciences, and the award of the 1 st Sowell-Huggins Professorship in Cancer Research in that school. I was the recipient of the Distinguished Research Faculty Mentor Award in 2013.
Present Title & Affiliation
Primary Appointment
Professor, Department of Experimental Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Research Interests
My research program melds discovery of mechanisms of drug action and an understanding of cancer cell biology to generate experimental strategies that improve therapeutic efficacy and aim to overcome potential means of tumor resistance. I have concentrated efforts on translational investigations with colleagues in the Leukemia Department.
Inhibition of DNA Repair. We have discovered that the mechanism of action of a nucleoside analogue now in early phase clinical trials, sapacitabine, is to generate a single strand break which is difficult to repair, and results in formation of a double-strand DNA break upon subsequent DNA replication. A homologous recombination mechanism is required to repair such lesions. Based on this information, we have initiated investigations of sapacitabine in tumors that lack the homologous recombination repair functions.
Cellular context as a basis for specificity. The survival of CLL is dependent upon the sustained expression of anti-apoptotic proteins, some of which (Mcl-1, XIAP) have intrinsic signals for rapid turnover of transcripts and protein. We reasoned that transient inhibition of transcription would decrease these proteins to the point of initiation of apoptosis, an irreversible process. Transcription requires phosphorylation of RNA polymerase II by cyclin-dependent kinase 9. Our investigations in primary CLL samples demonstrated that Cdk9 is potently inhibited by several small molecules, with a resulting decrease in RNA polymerase activity, transcript generation and decreased survival protein levels, that were associated with apoptosis induction within 8 hr. This has provided rationale for the development of this class of novel therapeutics in hematological malignancies.
Education & Training
Degree-Granting Education
| 1970 | University of Massachusetts, Amherst, MA, USA, PHD, Biochemistry |
| 1965 | Springfield College, Springfield, MA, USA, BS, Biology, Chemistry |
Postgraduate Training
| 1970-1971 | Postdoctoral Fellow, Therapeutic Research, University of Pennsylvania, Philadelphia, PA |
Experience & Service
Administrative Appointments/Responsibilities
Director, Therapeutics and Pharmacology Program, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX, 2017 - Present
Deputy Department Chair, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, 2008 - Present
Associate Vice President, Research Integrity, The University of Texas MD Anderson Cancer Center, Houston, TX, 2008 - Present
Institutional Research Integrity Officer, The University of Texas MD Anderson Cancer Center, Houston, TX, 2007 - Present
Other Appointments/Responsibilities
Chairman, Scientific Advisory Board, Chronic Lymphocytic Leukemia Global Research Foundation, Houston, 2004 - Present
Research Associate, University of Colorado Medical Center, Denver, CO, 1972 - 1975
Endowed Positions
Barnts Family Distinguished Chair for Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 1999 - Present
Hubert L. and Olive Stringer Professorship in Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1989 - 1999
Honors & Awards
| 2018 | Dr. John S. McMurray Lifetime TAP Achievement Award, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences |
| 2016 | John Mendelsohn Lifetime Scientific Achievement Award, Division of Cancer Medicine |
| 2013 | Distinguished Research Faculty Mentor Award, M.D. Anderson Cancer Center |
| 2013 | Charles A. LeMaistre M.D. Outstanding Achievement Award in Cancer, M.D. Anderson Cancer Center |
| 2012 | Co-Leader of CLL Moon Shot Program, M.D.Anderson Cancer Center Moon Shot Program |
| 2012 | Fellow, American Association for the Advancement of Science, American Association for the Advancement of Science |
| 2011 | Waun Ki Hong Achievement Award for Team Science - CLL, Division of Cancer Medicine |
| 2006 | 1st Potu N. Rao Award for Outstanding Achievement in Basic Science, The University of Texas MD Anderson Cancer Center, Division of Cancer Medicine |
| 2001 | 1st Sowell-Huggins Professorship in Cancer Research, University of Texas Graduate School of Biomedical Sciences, Houston |
| 1999 | Barnts Family Distinguished Chair for Cancer Research, The University of Texas M. D. Anderson Cancer Center |
| 1996 | Faculty Achievement Award, Clinical Research, The University of Texas M. D. Anderson Cancer Center |
| 1993 | Chairman, Gordon Research Conference on Purines, Pyrimidines & Related Substances |
| 1991 | Outstanding Faculty Award, University of Texas Graduate School of Biomedical Sciences at Houston |
| 1989 | Service to Mankind Award, Leukemia Society of America, Gulf Coast Chapter |
| 1989 | Hubert L. and Olive Stringer Professorship in Medical Oncology, The University of Texas M. D. Anderson Cancer Center |
| 1988 | President of the Graduate Faculty, University of Texas Graduate School of Biomedical Sciences |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Thompson PA, Bazinet A, Wierda WG, Tam CS, O'Brien SM, Saha S, Peterson C, Plunkett W, Keating MJ. Sustained remissions in CLL after frontline FCR treatment with very long-term follow-up. Blood. e-Pub 2023. PMID: 37595283.
- Chen R, Chen Y, Xiong P, Zheleva D, Blake D, Keating MJ, Wierda WG, Plunkett W. Cyclin-dependent kinase inhibitor fadraciclib (CYC065) depletes anti-apoptotic protein and synergizes with venetoclax in primary chronic lymphocytic leukemia cells. Leukemia 36(6):1596-1608, 2022. e-Pub 2022. PMID: 35383271.
- Jain N, Thompson P, Burger J, Ferrajoli A, Takahashi K, Estrov Z, Borthakur G, Bose P, Kadia T, Pemmaraju N, Sasaki K, Konopleva M, Jabbour E, Garg N, Wang X, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang S, Lopez W, Ayala A,Plunkett W, Gandhi V, Kantarjian H, O'Brien S, Keating M, Wierda WG. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. Leukemia 35(12):3421-3429, 2021. e-Pub 2021. PMID: 34007049.
- Jain N, Keating M, Thompson P, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Estrov Z, Sasaki K, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang SA, Garg N, Wang X, Wei C, Cruz N, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda WG. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial. JAMA Oncol 7(8):1213-1219, 2021. e-Pub 2021. PMID: 34110383.
- Chen R, Tsai J, Thompson PA, Chen Y, Xiong P, Liu C, Burrows F, Sivina M, Burger JA, Keating MJ, Wierda WG, Plunkett W,. The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of action. Blood Cancer J 11(3):57, 2021. e-Pub 2021. PMID: 33714981.
- Liu X, Jiang Y, Nowak B, Ichikawa S, Ohtawa M, Matsuda A, Plunkett W. Repair of DNA damage induced by the novel nucleoside analogue CNDAG through homologous recombination. Cancer Chemother Pharmacol. e-Pub 2020. PMID: 32072218.
- Liu X, Jiang Y, Takata KI, Nowak B, Liu C, Wood RD, Hittelman WN, Plunkett W. CNDAC-Induced DNA Double-Strand Breaks Cause Aberrant Mitosis Prior to Cell Death. Mol Cancer Ther 18(12):2283-2295, 2019. e-Pub 2019. PMID: 31501277.
- Banerjee P, Zhang R, Ivan C, Galletti G, Clise-Dwyer K, Barbaglio F, Scarfò L, Aracil M, Klein C, Wierda W,Plunkett W, Caligaris-Cappio F, Gandhi V, Keating MJ, Bertilaccio MTS. Trabectedin Reveals a Strategy of Immunomodulation in Chronic Lymphocytic Leukemia. Cancer Immunol Res 7(12):2036-2051, 2019. e-Pub 2019. PMID: 31530560.
- Luo Y, Yang Y, Liu M, Wang D, Wang F, Bi Y, Ji J, Li S, Liu Y, Chen R, Huang H, Wang X, Swidnicka-Siergiejko AK, Janowitz T, Beyaz S, Wang G, Xu S, Bialkowska AB, Luo CK, Pin CL, Liang G, Lu X, Wu M, Shroyer KR, Wolff RA, Plunkett W, Ji B, Li Z, Li E, Li X, Yang VW, Logsdon CD, Abbruzzese JL, Lu W. Oncogenic KRAS Reduces Expression of FGF21 in Acinar Cells to Promote Pancreatic Tumorigenesis in Mice on a High-Fat Diet. Gastroenterology 157(5):1413-1428.e11, 2019. e-Pub 2019. PMID: 31352001.
- Lai TH, Mitchell S, Wu PJ, Orwick S, Liu C, Ravikrishnan J, Woyach J, Mims A, Plunkett W, Puduvalli VK, Byrd JC, Lapalombella R, Sampath D. HSP90 inhibition depletes DNA repair proteins to sensitize acute myelogenous leukemia to nucleoside analog chemotherapeutics. Leuk Lymphoma 60(9):1-4, 2019. e-Pub 2019. PMID: 30773117.
- Chen R, Zhu M, Chaudhari RR, Robles O, Chen Y, Skillern W, Qin Q, Wierda WG, Zhang S, Hull KG, Romo D, Plunkett W. Creating novel translation inhibitors to target pro-survival proteins in chronic lymphocytic leukemia. Leukemia 33(7):1663-1674, 2019. e-Pub 2019. PMID: 30700841.
- Kantarjian HM, Jabbour EJ, Garcia-Manero G, Kadia TM, DiNardo CD, Daver NG, Borthakur G, Jain N, Waukau JB, Kwari MI, Ravandi F, Anderson BD, Iizuka K, Jin C, Zhang C, Plunkett W. Phase 1/2 study of DFP-10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia. Cancer 125(10):1665-1673, 2019. e-Pub 2019. PMID: 30668890.
- Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med 380(22):2095-2103, 2019. PMID: 31141631.
- Elsayed AH, Cao X, Crews KR, Gandhi V, Plunkett W, Rubnitz JE, Ribeiro RC, Pounds SB, Lamba JK. Comprehensive Ara-C SNP score predicts leukemic cell intracellular ara-CTP levels in pediatric acute myeloid leukemia patients. Pharmacogenomics 19(14):1101-1110, 2018. e-Pub 2018. PMID: 30088438.
- Short NJ, Kantarjian H, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Wierda WG, DiNardo CD, Brandt M, O'Brien SM, Cortes JE, Jabbour E. A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma 59(4):1-8, 2018. e-Pub 2017. PMID: 28718728.
- Liu X, Jiang Y, Nowak B, Qiang B, Cheng N, Chen Y, Plunkett W. Targeting BRCA1/2 deficient ovarian cancer with CNDAC-based drug combinations. Cancer Chemother Pharmacol 81(2):255-267, 2018. e-Pub 2017. PMID: 29189915.
Grant & Contract Support
| Title: | Chronic Lymphocytic Leukemia Research Consortium |
| Funding Source: | NIH |
| Role: | Project Leader |
| Title: | Biochemical Basis for Therapeutic Activity |
| Funding Source: | NIH |
| Role: | Principal Investigator |
| Title: | Creating Novel Translation Inhibitors to Target Pro-Survival Oncoproteins |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-Principal Investigator |
| Title: | Strategies to target the pathophysiology of CLL |
| Funding Source: | CLL Global Research Foundation |
| Role: | Principal Investigator |
| Title: | CLL moon shot - ibrutinib |
| Funding Source: | MDACC Moon Shot Program |
| Role: | Principal Investigator |
| Title: | Cancer Center Support (Core) Grant |
| Funding Source: | NIH/NCI |
| Role: | Program Leader |
| Title: | Single agent and mechanism-based combinations of CYC065 in chronic lymphocytic leukemia |
| Funding Source: | Cyclacel |
| Role: | Principal Investigator |
| Title: | SPORE University of Texas MD Anderson Cancer Center - Career Development Program (CDP) |
| Funding Source: | NIH/NCI |
| Role: | Co-Leader, Career Development Program |
| Title: | SPORE - University of Texas MD Anderson Cancer Center - Development Research Program (DRP) |
| Funding Source: | NIH/NCI |
| Role: | Co-Leader, Development Research Program |
| Title: | Strategies to understand and target Bcl-2 Family Proteins in CLL |
| Funding Source: | CLL Global Research Foundation |
| Role: | Principal Investigator |
| Title: | Evaluation of Biomarkers of CYC065 pharmacodynamics in the Phase 1 trial |
| Funding Source: | Cyclacel Pharmaceuticals |
| Role: | Principal Investigator |
| Title: | Project 3: Targeting CLL Pathophysiology |
| Funding Source: | The University of Texas MD Anderson Cancer Center, Moon Shots Program |
| Role: | Principal Investigator-MDACC |
| Title: | Apoptotic Correlative Analysis of Fadraciclib (MD Anderson CLL Subjects only) in a Phase ½ Trial |
| Funding Source: | Cyclacel Pharmaceuticals |
| Role: | Principal Investigator |
| Title: | Project 2: Curative Targeted Therapy of CLL |
| Funding Source: | The University of Texas MD Anderson Cancer Center, Moon Shots Program |
| Role: | Principal Investigator-MDACC |
Patient Reviews
CV information above last modified November 03, 2023